What It Does: Xylem is a water technology company providing smart metering (measuring water usage), treatment (purification, filtration), and analytics software. The company's Evoqua acquisition (2024, pending close) adds industrial water treatment and reuse capabilities. Xylem also manufactures water pumps and manages wastewater infrastructure. ESG tailwinds are powerful: water scarcity is rising, regulations demand conservation, and data-driven water management improves efficiency. Xylem generated $7.4B in FY2024 revenue, growing 7%+. The Evoqua deal adds $2.3B in revenue, creating a $9.7B water pure-play. Operating margins are 18%, expected to improve with Evoqua synergies.
How the Stock Looks: XYL trades near $135 with a market cap of $30 billion. The stock has appreciated 35% in the past 18 months, supported by Evoqua acquisition momentum and ESG tailwinds. Operating margins are 18%, with synergy potential. Free cash flow tops $1.2B annually. The valuation at 28x forward earnings is reasonable for a water infrastructure company with secular growth visibility. Key catalysts include Evoqua acquisition close, synergy realization commentary, quarterly water meter adoption metrics, ESG spending trends, and dividend growth announcements.
What Analysts Are Saying: 26 analysts rate XYL a Buy, with consensus price target of $145. Bullish analysts from Goldman Sachs and Morgan Stanley champion the Evoqua acquisition as transformative, creating a pure-play water infrastructure company. ESG regulations drive demand for smart metering and water reuse. Synergy potential is significant. Bears at JP Morgan note integration risk and economic cycle sensitivity. However, analyst consensus is constructive: water scarcity is secular, Evoqua synergies are achievable, and ESG tailwinds are durable. The stock is a beneficiary of resource scarcity and environmental regulation.